8.02
+0.12%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Anhui Anke Biotechnology Group Co
Its shares trade on Shenzhen under the ticker 300009.SZ. It has been listed since 30 October 2009. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.65bn and net income of CN¥735.2m. At that date it held total assets of CN¥5.55bn and shareholders' equity of CN¥4.56bn.
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the research, development, manufacturing, and sale of biopharmaceutical products. The company is headquartered in Hefei, Anhui. The company went IPO on 2009-10-30. The Company’s main products include recombinant human interferon alfa-2b series, recombinant human growth hormone, peptides Active Pharmaceutical Ingredients (APIs), customized peptides, deoxyribonucleic acid (DNA) fluorescence detection kit, silica beads extraction kit, anti-sperm antibody test kit, pain relieving ointment, amoxicillin granules and capsules, cefaclor dispersible tablets and adefovir dipivoxil tablets, among others. The firm distributes its products in domestic market and to overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Oct 2009
- Employees
- 3,003
- Website
- ankebio.com ↗
Leadership
Pay as last reported
- Mr. Lihua SongChairman of the Board, President, since 1993CN¥2.7m
- Mr. Jianping YaoExecutive PresidentCN¥857,000
- Mr. Liming SongVice Chairman of the Board, since 2003CN¥976,000
- Ms. Yuanyuan ZhouVice Chairman of the BoardCN¥635,000
- Mr. Chenghao HuChief Financial OfficerCN¥438,700
- Ms. Hui ZhaoSenior Vice President, DirectorCN¥651,000
- Mr. Hai ShengSenior Vice President, since 2019CN¥1.1m
- Mr. Xueke BaoVice PresidentCN¥1.1m
- Mr. Ta Wei ChouVice PresidentCN¥887,000
- Mr. Yinghui DouVice PresidentCN¥687,000
- Ms. Chunyan LuVice President, since 2019CN¥506,000
- Ms. Hongyi YaoVice PresidentCN¥531,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 25
- Environment
- 30
- Social
- 16
- Governance
- 29
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Anhui Anke Biotechnology Group Co Ltd employs 3003 employees in Hefei, CN.
- The company's recombinant human interferon alfa-2b series is a key product in biopharmaceuticals.
- Anhui Anke distributes products domestically and to overseas markets effectively.
Weaknesses
- The company's IPO date of 30 October 2009 may indicate limited market experience.
- Anhui Anke's product range includes amoxicillin granules and capsules, which face generic competition.
- The firm's focus on biopharmaceuticals may limit diversification in Health Care sector.
Opportunities
- Expanding recombinant human growth hormone sales in the Health Care sector.
- Increasing DNA fluorescence detection kit demand in biotechnology markets.
- Growing demand for anti-sperm antibody test kits in reproductive health care.
Threats
- Competition from other biopharmaceutical companies in the Health Care sector.
- Regulatory changes affecting biotechnology product approvals.
- Overreliance on domestic market distribution in CN for revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.